Efforts have been made to restore the crosstalk between DCs and CD4+ T cells by promoting DC maturation, which has shown promising results in conferring potent immunity in breast cancer with CDK4/6 inhibitors (CDK4/6i) and immune checkpoint blockade (ICB) therapy (83, 84). This evidence concerns the gene CDK4 and breast carcinoma.